# Kymera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kymera-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.kymeratx.com
- Total disclosed funding: $193M
- Latest round: Series C (Mar 12, 2020)
- Investors on record: 17

## About

Based in Massachusetts, US, and founded in 2016, Kymera Therapeutics, Inc. operates as a biotechnology company that develops therapeutics for cancer, autoimmune diseases, and inflammatory diseases. The company was founded by President and CEO Dr. Nello Mainolfi. In December 2025, Kymera Therapeutics, Inc. raised USD 692.3 million in a private placement, selling 8.05 million shares at USD 86.00 per share on the Nasdaq Global Select Market under the ticker symbol KYMR. 

Kymera Therapeutics is a biopharmaceutical company that focuses on advancing the field of targeted protein degradation by accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins to address previously intractable disease targets. The company’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes invalidated pathways currently inaccessible with therapeutics. Kymera Therapeutics’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat immune-inflammatory diseases, hematologic malignancies, and solid tumors.

## Funding rounds

- Series C, Mar 12, 2020, $101M — Bain Capital, Wellington Management, BlackRock, Redmile Group, BVF Partners, Rock Springs Capital, Janus Henderson Investors
- Series B, Nov 1, 2018, $65M — Hatteras Venture Partners, AJU IB Investment, Bessemer Venture Partners, Merck Global Health Innovation Fund, Pfizer Venture Investments, Sanofi Ventures, 6 Dimensions Capital
- Series A, Oct 30, 2017, $27M — Atlas Venture, Lilly Ventures, Amgen Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series B
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- Rock Springs Capital — Series C
- Janus Henderson Investors — Series C